008AE101-874B-4EB6-B811-3945E5ECCFD9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.363994743758212
- age_years
- 63
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.551
- E2F_TARGETS+0.550
- CHOLESTEROL_HOMEOSTASIS+0.543
- INTERFERON_ALPHA_RESPONSE+0.523
- ANGIOGENESIS+0.495
- MYC_TARGETS_V2+0.476
- NOTCH_SIGNALING+0.453
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.406
- INTERFERON_GAMMA_RESPONSE+0.394
- MTORC1_SIGNALING+0.383
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.241
- SPERMATOGENESIS-0.210
- KRAS_SIGNALING_DN-0.195
- HEDGEHOG_SIGNALING-0.143
- ALLOGRAFT_REJECTION+0.016
- MYOGENESIS+0.031
- KRAS_SIGNALING_UP+0.051
- BILE_ACID_METABOLISM+0.055
- INFLAMMATORY_RESPONSE+0.059
- UV_RESPONSE_DN+0.061
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 52F6F0A9-8D2D-49BC-9B49-E20E5E53561C | — | — | 0.930 |
| 2 | 633064DB-D3ED-4B5F-B48F-6924AD719647 | — | — | 0.923 |
| 3 | SRR934860 | — | — | 0.921 |
| 4 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.920 |
| 5 | 2566FDAC-EF10-4996-8890-FA0BEC771676 | — | — | 0.918 |
| 6 | 6794CB9F-5326-4F57-B2E2-5D877C03F5D4 | — | — | 0.916 |
| 7 | C5C8713B-05C1-4C5C-8685-2A546B99BA50 | — | — | 0.916 |
| 8 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.915 |
| 9 | C3F0BD22-6891-44F0-B023-02FC6EDFA7EB | — | — | 0.913 |
| 10 | 33800B09-6DCC-4BE8-891C-5F34ADAC65B3 | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 46 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.551 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.543 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.523 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.495 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.476 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.453 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.406 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.394 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.383 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.352 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.351 | Inavolisib | — uncovered |
| APOPTOSIS | 0.349 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.348 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.348 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.335 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.312 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.299 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.297 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.289 | Idelalisib | — uncovered |